Noxopharm.jpg
Positive DARRT-1 Data in Late-Stage Prostate Cancer
December 02, 2019 09:00 ET | Noxopharm
Clinical responses point to the NOX66 DARRT treatment regimen as a potentially major new treatment option for men with late-stage prostate cancerPositive results trigger planning for proposed pivotal...
Noxopharm.jpg
Noxopharm Announces Appointment of Chief Commercial Officer
November 06, 2019 09:26 ET | Noxopharm
Noxopharm has appointed Mr Alexander Hunter as Chief Commercial OfficerMr Hunter is an experienced corporate finance and business executive with a background in high growth listed company operations...
Noxopharm.jpg
Potential for Fundamental Change in the Treatment of Brain Cancer
October 18, 2019 09:13 ET | Noxopharm
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancerBased on recent international...
Noxopharm.jpg
Further Data Review Shows Major Clinical Benefits From Veyonda®
September 30, 2019 08:00 ET | Noxopharm
Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer177LuPSMA therapy is the subject of a recent...
Noxopharm.jpg
Veyonda® and Radiotherapy Profiled at Key Oncology Meeting
September 17, 2019 11:01 ET | Noxopharm
Research relating to Veyonda® in the treatment of advanced prostate cancer is to be included in a key Australian oncology meetingBoth Noxopharm and independent investigators have abstracts...
Noxopharm.jpg
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results
August 28, 2019 07:57 ET | Noxopharm
SYDNEY, Australia, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on...
Noxopharm.jpg
Pre-Clinical Evidence Confirms Veyonda® Abscopal Effect
August 21, 2019 08:12 ET | Noxopharm
Veyonda® is being developed as a transformative anti-cancer treatment (DARRT) in combination with radiotherapy to produce off-target responses known as an abscopal effectPre-clinical studies now...
Noxopharm.jpg
Appendix 4C– June 2019 Quarter
July 29, 2019 08:00 ET | Noxopharm
Positive results from two prostate cancer trialsPhase 2 trial design gaining momentumInvestigational New Drug Application to be submitted to FDA in Q3 2019Pipeline developing based on drug discovery...